Pharvaris N.V.
PHVSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Pharvaris N.V. focuses on Biotechnology services and products. Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other. The company carries a $2.09B market cap, placing it firmly in the mid-cap category. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Market Cap
$2.09B
Beta
-2.33
P/E (TTM)
—
P/E (Fwd)
-10.94
EPS (TTM)
$-3.16
EPS (Fwd)
$-2.73
ROE
-73.0%
ROA
-42.3%
Cash
$247.0M
Total Debt
$738,891
Free CF
-$87.7M
52W Change
79.9%
Annual Financials
Cash vs Debt
Pharvaris N.V. holds $247.0M in cash against $739K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$87.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -73.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Pharvaris N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, PHVS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PHVS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.